# Hepatitis A Vaccine in Patients With Immunomodulating Drugs

> **NCT01360970** · PHASE2 · COMPLETED · sponsor: **Lars Rombo** · enrollment: 68 (actual)

## Conditions studied

- Response to Hepatitis A Vaccine

## Interventions

- **BIOLOGICAL:** hepatitis A vaccine ( HAVRIX or EPAXAL)

## Key facts

- **NCT ID:** NCT01360970
- **Lead sponsor:** Lars Rombo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360970, "Hepatitis A Vaccine in Patients With Immunomodulating Drugs". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01360970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*